Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer (Q33366766)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer |
scientific article |
Statements
1 reference
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer (English)
1 reference
Max E Scheulen
1 reference
Stephen Johnston
1 reference
Klaus Mross
1 reference
Christian Dittrich
1 reference
Dagmar Hess
1 reference
Rudolph Morant
1 reference
Markus Borner
1 reference
Marc Salzberg
1 reference
Valerijus Ostapenko
1 reference
Hans-Joachim Illiger
1 reference
Dirk Behringer
1 reference
Nathalie Bardy-Bouxin
1 reference
Joseph Boni
1 reference
Steven Kong
1 reference
Maria Cincotta
1 reference
Laurence Moore
1 reference
1 reference
Identifiers
1 reference